Clinical Scorecard: Comparative Analysis of Two Instillation Protocols of Intravesical Hyaluronic Acid and Chondroitin Sulphate for Women with Recurrent Urinary Tract Infections: A Prospective Multicenter Study

At a Glance

Key Highlights

• 140 women enrolled, divided into two treatment groups.
• Both treatment protocols significantly reduced UTI recurrence over 12 months.
• No significant difference in UTI frequency between the two groups (0.6 vs 0.7 episodes).
• Improvements observed in urinary symptoms and pelvic pain.
• No serious adverse events reported.

Guideline-Based Recommendations

Diagnosis

• Recurrent urinary tract infections defined as two or more symptomatic episodes over six months or three episodes during one year with positive urine cultures.

Management

• Intravesical administration of HA and CS as a non-antibiotic preventive strategy for r-UTIs.

Monitoring & Follow-up

• Clinical evaluation, bladder diary, uroflowmetry, post-void residual, pelvic-pain VAS, urinalysis, urine culture, and ICIQ-FLUTS questionnaire at baseline and follow-ups.

Risks

• Potential for antimicrobial resistance and adverse drug reactions with prolonged antibiotic use.

Patient & Prescribing Data

Women with recurrent urinary tract infections.

Two distinct intravesical instillation protocols were evaluated for safety and effectiveness.

Clinical Best Practices

• Consider intravesical HA and CS for women with recurrent urinary tract infections.
• Follow EAU guidelines for diagnosis and management of r-UTIs.

Related Resources & Content

• European Association of Urology Guidelines